Laurus Labs Limited

NSE LAURUSLABS.NS

Laurus Labs Limited Price to Sales Ratio (P/S) on January 14, 2025: 5.66

Laurus Labs Limited Price to Sales Ratio (P/S) is 5.66 on January 14, 2025, a 55.82% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Laurus Labs Limited 52-week high Price to Sales Ratio (P/S) is 6.76 on January 07, 2025, which is 19.47% above the current Price to Sales Ratio (P/S).
  • Laurus Labs Limited 52-week low Price to Sales Ratio (P/S) is 3.29 on January 30, 2024, which is -41.86% below the current Price to Sales Ratio (P/S).
  • Laurus Labs Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 4.79.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
NSE: LAURUSLABS.NS

Laurus Labs Limited

CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
IPO Date Dec. 19, 2016
Location India
Headquarters Serene Chambers
Employees 6,007
Sector Health Care
Industries
Description

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.

Similar companies

DEEPAKNTR.NS

Deepak Nitrite Limited

USD 27.05

0.71%

SYNGENE.NS

Syngene International Limited

USD 9.56

0.73%

IEX.NS

Indian Energy Exchange Limited

USD 1.93

3.86%

DIXON.NS

Dixon Technologies (India) Limited

USD 188.04

2.93%

DIVISLAB.NS

Divi's Laboratories Limited

USD 69.21

4.65%

StockViz Staff

January 15, 2025

Any question? Send us an email